TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06785012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-89495120
Description: JNJ-89495120 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-89495120
Description: JNJ-89495120 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06785558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic therapy
Description: Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
Study: NCT06787196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, single-dose, 8 mg IV administered intraoperatively
Study: NCT06783517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cerabone
Description: Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone graft (cerabone®,Botiss biomaterial) will be added to the implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cerabone®plus
Description: Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone substitute with sodium hyaluronate graft (cerabone®plus,Botiss biomaterial) will be added to the implant
Study: NCT06785675

Intervention type: OTHER
Intervention: Secukinumab
Description: This is an observational study. There is no treatment allocation.
Study: NCT06786052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: After randomization, participants will consume the probiotic for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, participants will consume the placebo for 3 months.
Study: NCT06785545

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CA19-9
Description: All patients Ca19-9 levels calculated from their urinary samples

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CA19-9
Description: All patients Ca19-9 levels calculated from their urinary samples

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CA19-9
Description: All patients Ca19-9 levels calculated from their urinary samples
Study: NCT06780592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebreltinib + Temozolomide
Description: Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
Study: NCT06776172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pelvic Lymph Node Dissection
Description: Extended pelvic lymph node dissection during radical prostatectomy
Study: NCT06783608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). Patients were asked to measure and record their blood glucose value before breakfast. The yoga session was started 30 minutes after breakfast, and after the session was completed, they were asked to measure and record their blood glucose value again at 120 minutes after breakfast.
Study: NCT06786923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulator
Description: Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).
Study: NCT06782750

Intervention type: OTHER
Intervention: Physiotherapy
Description: Traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks.
Study: NCT06784050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Balanced Occlusion
Description: Dentures designed under this scheme feature a fully bilateral balanced articulation, ensuring bilateral, simultaneous contact of the anterior and posterior denture teeth in both centric and eccentric positions. This occlusal scheme is aimed at promoting stability and functionality of the dentures during various mandibular movements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monoplane Occlusion
Description: This scheme utilizes zero-degree teeth to create a flat occlusal plane, which is designed to simplify the occlusal contacts and minimize the transmission of lateral forces during mastication. The aim is to improve masticatory efficiency by reducing the complexity of tooth contact
Study: NCT06784323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Catered diet
Description: For a period of 8 weeks the participant will receive catered food, the study team will provide the participants breakfast, lunch and dinner. Participants will receive catered food for 3 daily meals, and record daily food intake. Catered diet will be sent to participants' homes on a weekly basis. The diet will consist of primarily whole foods with few additives, with a focus on Hispanic cultural foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Catered diet
Description: For a period of 8 weeks the participant will receive catered food, the study team will provide the participants breakfast, lunch and dinner. Participants will receive catered food for 3 daily meals, and record daily food intake. Catered diet will be sent to participants' homes on a weekly basis. The diet will consist of primarily whole foods with few additives, with a focus on Hispanic cultural foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet guidance sessions
Description: Participants will receive virtual weekly diet guidance with a dietitian regarding food safety preparation methods and cooking practices. Patients will receive weekly gift cards for grocery stipend. On average, initial counseling session with dietitian will last 30 minutes, and 7 follow-up sessions will last 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet guidance sessions
Description: Participants will receive virtual weekly diet guidance with a dietitian regarding food safety preparation methods and cooking practices. Patients will receive weekly gift cards for grocery stipend. On average, initial counseling session with dietitian will last 30 minutes, and 7 follow-up sessions will last 20 minutes.
Study: NCT05509998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Communication Method (SCM)
Description: Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
Study: NCT06608095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypothermia group
Description: Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normothermia group
Description: Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
Study: NCT06608017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine granules
Description: Treatment group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group
Study: NCT06610097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as (1) a 60-minute initial telehealth consultation within the first week of study enrollment, and (2) up to two 30-minute follow-ups throughout the study, ideally the first follow-up within 6 weeks of study enrollment. These sessions will be led by a registered dietitian using cultural awareness and symptom assessment.
Study: NCT04729751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base
Study: NCT06612684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezoelectric syndesmotomy
Description: Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
Study: NCT06612047

Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
Study: NCT05122455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
Study: NCT06784323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: Participants will receive dietary counseling weekly on Zoom for up to 30 minutes. Dietitian will meet with participants to explain benefits of adhering to diet therapy.
Study: NCT05122455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
Study: NCT05542251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Educational Program
Description: The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
Study: NCT06784323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: Participants will receive dietary counseling weekly on Zoom for up to 30 minutes. Dietitian will meet with participants to explain benefits of adhering to diet therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback sessions
Description: Participants will be involved in one-time 50-minute feedback session over Zoom with dietitian and principal investigator. During the session, participants will discuss preferred foods/recipes during active disease, likeability of recipes, ease of recipe preparation, dietary adherence, and healthy food affordability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback sessions
Description: Participants will be involved in one-time 50-minute feedback session over Zoom with dietitian and principal investigator. During the session, participants will discuss preferred foods/recipes during active disease, likeability of recipes, ease of recipe preparation, dietary adherence, and healthy food affordability.
Study: NCT06785623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrodia elata Blume water extract
Description: Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gastrodia elata Blume water extract
Description: Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
Study: NCT06786481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational with milnacipran
Description: Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locally Directed Therapy
Description: Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again.
Study: NCT06786312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, P.O, qd, 21 days per cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: 100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
Study: NCT06783712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) + iPACK Block
Description: Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally